CTLA4 and cancer: We used a model in which inbred mice bearing tumors derived from monoclonal cancer cell lines respond dichotomously to anti-CTLA-4 and anti-PD-L1 ICT, with some mice experiencing complete tumor regression within days, and the others not responding to therapy (22).